Sana Biotechnology, Inc. (SANA): Price and Financial Metrics
GET POWR RATINGS... FREE!
SANA Stock Price Chart Interactive Chart >
SANA Price/Volume Stats
| Current price | $4.93 | 52-week high | $26.60 |
| Prev. close | $4.53 | 52-week low | $4.15 |
| Day low | $4.40 | Volume | 1,650,200 |
| Day high | $5.09 | Avg. volume | 1,362,689 |
| 50-day MA | $7.02 | Dividend yield | N/A |
| 200-day MA | $14.00 | Market Cap | 935.06M |
Sana Biotechnology, Inc. (SANA) Company Bio
Sana Biotechnology, Inc. operates as a biotechnology company. The Company focuses on creating and delivering engineered cells as medicine for patients. Sana Biotechnology replaces damaged cells and tissues and treats broad array of diseases.
Latest SANA News From Around the Web
Below are the latest news stories about Sana Biotechnology Inc that investors may wish to consider to help them evaluate SANA as an investment opportunity.
Biotech IPOs Have Slowed to a Snail's PaceDecline tied to falling stock prices of newly minted companies |
INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANTInvaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors. |
Sana Biotechnology: Exciting Preclinical ScienceNo summary available. |
3 Biotechs That Will Soar Regardless of COVID-19In the healthcare markets, much time and energy have been focused on COVID-19. But there are some amazing opportunities outside the COVID space. |
Sana Biotechnology Inks Two Licensing Pacts For Targets Against Hematological MalignanciesSana Biotechnology Inc (NASDAQ: SANA) has obtained non-exclusive commercial rights to a clinically validated fully-human BCMA CAR construct from IASO Biotherapeutics and Innovent Biologics. The constructs can be used in certain in vivo gene therapy and ex vivo hypoimmune cell therapy applications. IASO Bio and Innovent will receive an upfront payment and are entitled to receive up to approximately $204 million in potential development and regulatory milestone payments across up to six products, |
SANA Price Returns
| 1-mo | -34.00% |
| 3-mo | -23.92% |
| 6-mo | -72.26% |
| 1-year | -76.49% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -68.15% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...